Domestic medical insurance status of capmatinib

Capmatinib (Capmatinib), this TKI drug, was first discovered in 2011 to be effective in type ib parathyroid tumors. After years of research and clinical trials, the drug was approved by the U.S. Food and Drug Administration (FDA) in August 2022 for the treatment of advanced non-small cell lung cancer with exon 14 skipping mutations. Its efficacy was verified in the GEOMETRY mono-1 study and showed significant therapeutic effects on lung cancer patients with MET exon 14 skipping mutations. This also prompted the FDA to approve the marketing of capmatinib and recommend its use in combination with the Foundation One CDx test to assist diagnosis.

As a prescription drug, the treatment process of capmatinib needs to be carried out under the guidance of a doctor with rich experience in cancer treatment. Before starting treatment, patients need genetic testing to confirm whether the METex14 skipping mutation is present in their cancer. This medication is available as an oral tablet and the recommended dosage is 400 mg twice daily. Treatment can continue as long as the patient continues to benefit from it. However, if serious side effects occur, your doctor may consider reducing the dose, or interrupting or even stopping treatment.

As for the market dynamics of capmatinib, the original research version of this innovative drug has not yet been officially launched in the domestic market, so it has not yet been included in the scope of medical insurance. However, the original drug of capmatinib is already available in the Hong Kong market. At the same time, the European version of capmatinib’s original drug is also sold in overseas markets. In addition, there are also generic drugs of capmatinib on the overseas market. Their drug ingredients are basically the same as the original drug, but there may be certain differences in price, providing patients with more choices.